VIDEO: Venetoclax plus R-EPOCH induces remissions in Richter’s syndrome
Click Here to Manage Email Alerts
In a video, Matthew S. Davids, MD, MMSc, from the Dana-Farber Cancer Institute, discussed data from his study of venetoclax plus R-EPOCH chemotherapy for Richter’s syndrome presented at ASCO20 Virtual Scientific Program.
“[The study] is looking at this very high-risk population of patients who had CLL, but then transformed into more aggressive Richter’s syndrome, where the median overall survival, historically, has only been in the range of about 3 to 6 months with traditional chemo-based therapy regimens,” he told Healio.
Davids reported that in this phase 2 study, the CR rate was 50% in the intent-to-treat analysis, the regimen controlled patients’ CLL disease and the median overall survival was 16.3 months.
Collapse
Davids MS, et al. Abstract 8004. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Click Here to Manage Email Alerts